Boehringer Ingelheim
Trending Articles
Related Content
Research & Development
Boehringer Ingelheim ramps up its oncology ADC development with new tech and antigen target
The company has licensed Lonza-owned Synaffix's ADC platform technology, while also claiming the rights to a fourth novel oncology target from an ongoing discovery partnership with Oxford BioTherapeutics